Table 4

Cohort characteristics for overall patient cohort and age-determined cohorts in PD-1 inhibitor monotherapy subgroup

Overall N (%)
(n=374)
<65 years N (%)
(n=146)
65–74 years N (%) (n=127)≥75 years N (%) (n=101)X2
All grade≥G3All grade≥G3All grade≥G3All grade≥G3All grade≥G3
All toxicity203 (54.3)35 (9.4)76 (52.1)13 (8.9)74 (58.3)16 (12.6)54 (53.5)6 (5.9)NSNS
Adverse event
Dermatitis77 (20.6)2 (0.5)25 (17.1)0 (0.0)24 (18.9)0 (0.0)28 (27.7)2 (2.0)NSNS
Lower GI46 (12.3)9 (2.4)14 (9.6)6 (4.1)18 (14.2)2 (1.6)14 (13.9)1 (1.0)NSNS
Endocrine71 (19.0)8 (2.1)36 (24.7)3 (2.1)24 (18.9)4 (3.1)11 (10.9)1 (1.0)0.007NS
Hepatitis34 (9.1)5 (1.3)17 (11.6)0 (0.0)12 (9.4)4 (3.1)5 (5.0)1 (1.0)NSNS
Rheumatological15 (4.0)2 (0.5)3 (2.1)0 (0.0)7 (5.5)2 (1.6)5 (5.0)0 (0.0)NSNA
Other60 (16.0)12 (3.2)23 (15.7)4 (2.7)26 (20.5)7 (5.5)11 (10.9)1 (1.0)NSNS
Overall N (%)
(n=243)
<65 years N (%)
(n=81)
65–74 years N (%) (n=88)≥75 years N (%)
(n=74)
X2
Median no of cycles7 (1–60)5 (1–60)7 (1–49)8 (1–33)NA
Discontinuation due to toxicity14 (5.8)7 (8.6)5 (5.7)2 (2.7)NS
  • A total of 374 patients overall for which toxicity data are known, 243 patients for which continuation/discontinuation data are known.

  • GI, gastrointestinal; NA, Insufficient patient numbers for analysis; NS, not significant.